Zacks Investment Research Lowers Amneal Pharmaceuticals (NYSE:AMRX) to Sell

Zacks Investment Research downgraded shares of Amneal Pharmaceuticals (NYSE:AMRX) from a hold rating to a sell rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. “

Several other equities analysts have also issued reports on the stock. Raymond James boosted their price target on shares of S&P Global from $226.00 to $246.00 and gave the company an outperform rating in a report on Wednesday. Cantor Fitzgerald reissued an overweight rating and issued a $130.00 price target (up previously from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. BMO Capital Markets upped their target price on shares of Sun Life Financial from C$58.00 to C$60.00 in a research note on Friday, May 10th. SunTrust Banks initiated coverage on shares of Zoetis in a research note on Tuesday, March 19th. They issued a hold rating and a $100.00 target price for the company. Finally, ValuEngine lowered shares of Whiting USA Trust II from a hold rating to a sell rating in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. Amneal Pharmaceuticals presently has an average rating of Hold and a consensus target price of $14.58.



Shares of AMRX stock traded down $0.31 on Wednesday, hitting $4.05. The stock had a trading volume of 4,424,718 shares, compared to its average volume of 1,140,625. Amneal Pharmaceuticals has a twelve month low of $4.02 and a twelve month high of $24.48. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 4.26, a P/E/G ratio of 0.41 and a beta of 1.51. The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11. The company has a fifty day simple moving average of $7.21.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The firm had revenue of $446.00 million during the quarter, compared to analyst estimates of $438.18 million. Amneal Pharmaceuticals’s revenue for the quarter was up 4.9% on a year-over-year basis. Research analysts expect that Amneal Pharmaceuticals will post 0.91 earnings per share for the current year.

In related news, SVP Pradeep Bhadauria bought 7,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The stock was purchased at an average cost of $8.48 per share, with a total value of $59,360.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Andrew S. Boyer bought 19,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $9.46 per share, with a total value of $179,740.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 41,000 shares of company stock valued at $387,300. Company insiders own 26.34% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRX. Bessemer Group Inc. acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $34,000. Quantamental Technologies LLC boosted its stake in shares of Amneal Pharmaceuticals by 34.0% during the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock worth $95,000 after buying an additional 1,700 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Amneal Pharmaceuticals by 785.6% during the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock worth $166,000 after buying an additional 10,347 shares during the last quarter. First Mercantile Trust Co. boosted its stake in shares of Amneal Pharmaceuticals by 40.9% during the 1st quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock worth $169,000 after buying an additional 3,461 shares during the last quarter. Finally, Amalgamated Bank acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $174,000. 36.05% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Article: What is a capital gains distribution?

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.